Dr. Xiayang Qiu, founder CEO of Regor Therapeutics Group, is a visionary leader and expert in structural-based drug design across therapeutic areas and modalities. He established the Regor CARD (Computer Accelerate Rational Discovery) technology platform, which has delivered a dozen development candidates for major unmet needs. Notably, these include the leading oral small molecule GLP-1R full agonist RGT-075 for obesity (US phase 2b clinical trial readout in December 2025) and associated comorbidities, and the unique CDK4+ inhibitor RGT-419B potentially as a next generation standard therapy for breast cancers ($850M upfront deal with Roche/Genentech).
Prior to founding Regor, Dr. Qiu built and led industry-leading teams in broad disciplines of structural and molecular sciences and established the first high-resolution cryo-EM laboratory in industry. He is a key inventor of the RSV vaccine Abrysvo, the world’s first vaccine approved for maternity immunization to prevent infant infections. He also made a seminal scientific discovery for PCSK9 that drove industry-wide focus on antibody development for cardiovascular diseases.